Bay 11-7821 (BAY 11-7082): Selective IKK Inhibitor for NF-κB Pathway Research

Executive Summary: Bay 11-7821, also known as BAY 11-7082, is a well-characterized, cell-permeable inhibitor of IκB kinase (IKK) with an IC₅₀ of 10 μM, widely used for interrogating the NF-κB signaling pathway in inflammation and cancer research (Yang et al., 2022). It blocks TNFα-mediated phosphorylation of IκB-α, suppressing downstream expression of adhesion molecules (E-selectin, VCAM-1, ICAM-1) and attenuating NALP3 inflammasome activation in macrophages (APExBIO). Bay 11-7821 demonstrates anti-proliferative effects in NCI-H1703 lung cancer cells at concentrations up to 8 μM and induces apoptosis in B-cell lymphoma and leukemic T cells. In vivo, intratumoral delivery at 2.5–5 mg/kg twice weekly inhibits gastric cancer xenograft growth. The compound is insoluble in water, highly soluble in DMSO, and should be stored at -20°C for stability.

Biological Rationale

The NF-κB pathway is a master regulator of inflammatory gene expression and cell survival. Aberrant activation of this pathway is implicated in cancer, autoimmune disease, and sepsis. IκB kinase (IKK) is a key regulatory node, phosphorylating IκB-α and enabling NF-κB nuclear translocation. Inhibition of IKK prevents NF-κB activation and gene expression of inflammatory mediators, including adhesion molecules and cytokines. Bay 11-7821 was developed to selectively disrupt this signaling axis, providing a tractable tool for dissecting inflammation, apoptosis, and immune signaling (see comparative analysis—this article provides updated benchmarks and mechanistic links to HMGB1/lactate signaling).

Mechanism of Action of Bay 11-7821 (BAY 11-7082)

Bay 11-7821 targets the ATP-binding site of IKK, inhibiting kinase activity with an IC₅₀ of 10 μM under cell-free conditions (Yang et al., 2022). It blocks TNFα-induced phosphorylation of IκB-α in cultured cells, thereby preventing the release and nuclear translocation of NF-κB. This cascade blockade downregulates expression of E-selectin, VCAM-1, and ICAM-1. Bay 11-7821 also suppresses NALP3 inflammasome activation in macrophages, reducing secretion of pro-inflammatory cytokines. The compound induces apoptosis in lymphoid malignancies by interfering with NF-κB-dependent survival signals.

Evidence & Benchmarks

• Bay 11-7821 inhibits IKK with an IC₅₀ of 10 μM in biochemical assays (APExBIO).
• Suppresses TNFα-mediated phosphorylation of IκB-α and subsequent NF-κB activation in multiple cell lines at 2–10 μM (Yang et al., 2022).
• Reduces expression of E-selectin, VCAM-1, and ICAM-1 in endothelial and immune cells at 5–10 μM (APExBIO).
• Blocks NALP3 inflammasome activation and downstream IL-1β secretion in macrophage assays (Yang et al., 2022).
• Induces apoptosis and cell death in B-cell lymphoma and leukemic T cells at 6–10 μM (Cal101.net; this article extends translational and immuno-oncology use cases).
• Suppresses proliferation in NCI-H1703 non-small cell lung cancer cells at up to 8 μM (Egg-White-Lysozyme.com; this article incorporates new benchmarks vs. prior reviews).
• Inhibits tumor growth and induces apoptosis in human gastric cancer xenografts with intratumoral injections of 2.5–5 mg/kg, twice weekly (APExBIO).
• Solubility: ≥64 mg/mL in DMSO, ≥10.64 mg/mL in ethanol with warming and sonication; insoluble in water (APExBIO).

Applications, Limits & Misconceptions

Bay 11-7821 is widely used in inflammatory signaling pathway research, apoptosis regulation studies, and cancer research, notably in models of lymphoma, leukemia, and lung and gastric cancers. It is also utilized to dissect the role of NF-κB and inflammasome signaling in immune cell function.

For advanced protocol guidance, see Bay 11-7821: Precision IKK Inhibitor for NF-κB Pathway Research (this article updates comparative benchmarks), and Advanced IKK Inhibitor Use-Cases (this article clarifies practical workflow integration and troubleshooting).

Common Pitfalls or Misconceptions

• Non-specific effects at high concentrations: Concentrations >20 μM may cause off-target effects unrelated to IKK inhibition.
• Water insolubility: Bay 11-7821 is not water-soluble; improper solvent use leads to precipitation and loss of activity.
• Not a clinical drug: Bay 11-7821 is for research use only and lacks regulatory approval for therapeutic use.
• Rapid degradation in solution: Prepared solutions should not be stored long-term; single-use aliquots are recommended.
• No direct effect on upstream TNFα production: Bay 11-7821 inhibits downstream signaling, not TNFα synthesis.

Workflow Integration & Parameters

Bay 11-7821 (BAY 11-7082) is supplied by APExBIO (SKU: A4210) in powder form. For experimental use, dissolve in DMSO to ≥64 mg/mL or in ethanol to ≥10.64 mg/mL with gentle warming and ultrasonication. It is insoluble in aqueous buffers. Typical cell-based assay concentrations range from 2–10 μM. For in vivo studies, intratumoral injection of 2.5–5 mg/kg (twice weekly) is effective in tumor models. Store powder at -20°C; avoid repeated freeze-thaw cycles and prolonged storage of stock solutions.

For protocol optimization and troubleshooting, see Advanced IKK Inhibitor Use-Cases (this article adds new mechanistic insights and assay guidance).

For ordering and specifications, visit the Bay 11-7821 (BAY 11-7082) product page on APExBIO.

Conclusion & Outlook

Bay 11-7821 is a benchmark IKK inhibitor for NF-κB pathway research, providing robust, reproducible inhibition of inflammatory and survival signaling. Its mechanistic clarity, validated benchmarks, and broad applicability underpin its status as a gold-standard research tool. As studies expand into HMGB1/lactate signaling and inflammasome biology (Yang et al., 2022), Bay 11-7821 will remain integral to dissecting complex immune and oncogenic pathways.